My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$COP {{ '2015-07-30T17:08:56+0000' | timeago}} • Webcast

$COP 2Q15 Q&A: Douglas from Evercore asked about discretion and development programs deepwater reductions. Jeff, CFO, explained says that we talked about deflation capturing efficiency that we are seeing in the portfolio to lower the capital or required to keep flat production overtime.

User ritesh salot {{ '2017-01-24T14:22:47+0000' | timeago}}

Baba

User Robert Smith {{ '2017-01-24T13:01:54+0000' | timeago}}

$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?

User Charles Elliston {{ '2017-01-23T20:14:24+0000' | timeago}}

A federal judge has upheld the DOJ’s decision to block the $AET-$HUM merger.

User Josh Allan {{ '2017-01-23T20:10:30+0000' | timeago}}

$YHOO is reporting today after market close. Nobody cares about this stock.

User RC xNair {{ '2017-01-23T13:41:30+0000' | timeago}}

Excellent results from $MCD

$NEOG {{ '2017-01-24T15:10:10+0000' | timeago}} • Announcement

$NEOG terminated its agreement with $SNES related to the manufacturing and marketing of a rodenticide being developed by $SNES. The two firms had worked together since 2014, prior to the time when the $SNES product was approved by the U.S. Environmental Protection Agency.

$STBA {{ '2017-01-24T15:03:13+0000' | timeago}} • Announcement

$STBA's BoD declared a quarterly cash dividend of $0.20 per share. This is an increase of 5.3% compared to dividend of $0.19 per share declared in the same period in the prior year. The annualized yield using the Jan. 23, 2017 closing price of $37.12 is $2.2%. The dividend is payable on Feb. 23, 2017 to shareholders of record on Feb. 9, 2017.

$JNJ {{ '2017-01-24T15:02:44+0000' | timeago}} • Webcast

In pharma business, $JNJ expects to file 10 new products by 2019, each with at least $1Bil of potential sales. The company plans to file an additional 40 line extensions by 2019, 10 of which have more than $500MM in potential sales. In the medical devices business, $JNJ aims to return to above market growth by 2H17.

$MMM {{ '2017-01-24T15:01:45+0000' | timeago}} • Webcast

$MMM stated that regarding the underlying price growth in the US, the company's fundamental pricing power is not changing and is strong. Additionally, in the US, the company added that it took some targeted actions to help drive organic volume growth.

$VZ {{ '2017-01-24T15:01:02+0000' | timeago}} • Webcast

$VZ said that total revenue for 2017 would include the revenue of AOL, XO Communications, and possibly $YHOO if the transaction is closed. The company said IoT business will also see growth due to the Fleetmatics and Telogis acquisitions.